Billing and Coding: MolDX: Prolaris Prostate Cancer Genomic Assay for Men with Favorable Intermediate Risk Disease - R2 - Effective January 01, 2021

This coverage article has been revised and published for notice under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV).

Effective Date: January 01, 2021
Summary of Changes: Removal of 0228U under Group I CPT coding due to typographical error.

Visit the Molecular Diagnostic Services (MolDX) webpage to access the locally hosted MolDX Medicare Coverage Article from the “Covered Tests” or the “Excluded Tests” webpage.

To view the complete listing of locally hosted coverage articles and/or access the Active, Future, or Retired articles available in the CMS MCD, visit the Medicare Coverage Articles webpage.

            Last Updated Wed, 21 Apr 2021 17:29:57 +0000